Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie C Ward

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Atherosclerosis|May 23, 2022
Lipoprotein (a) and diabetes mellitusClaudia Lamina, Natalie C Ward
Journal of Clinical Lipidology|June 28, 2018
PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?Natalie C Ward, Gerald F Watts
Clinical and Experimental Pharmacology & Physiology|August 23, 2006
Hypertension and oxidative stressNatalie C Ward, Kevin D Croft
The Lancet. Diabetes & Endocrinology|April 2, 2021
A compass for navigating the perils of hypertriglyceridaemiaGerald F Watts, Natalie C Ward
Heart, Lung & Circulation|January 20, 2021
Extrinsic and Intrinsic Responses in the Development and Progression of AtherosclerosisMariya Kuk, Natalie C Ward, Girish Dwivedi
Current Opinion in Endocrinology, Diabetes, and Obesity|November 24, 2020
Lipoprotein (a) and diabetes mellitus: causes and consequencesNatalie C Ward, Shayimeera Vickneswaran, Gerald F Watts
Current Opinion in Cardiology|December 22, 2018
The gut microbiome and heart failureAdilah F Ahmad, Natalie C Ward, Girish Dwivedi
Current Opinion in Lipidology|October 3, 2019
Lipid management in people with peripheral artery diseaseJonathan Golledge, Natalie C Ward, Gerald F Watts
Diabetes, Obesity & Metabolism|April 20, 2019
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodiesNatalie C Ward, Michael M Page, Gerald F Watts
Frontiers in Cardiovascular Medicine|December 12, 2022
Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intoleranceNatalie C Ward, Christopher M Reid, Gerald F Watts
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Atherosclerosis|May 23, 2022
Lipoprotein (a) and diabetes mellitusClaudia Lamina, Natalie C Ward
Journal of Clinical Lipidology|June 28, 2018
PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?Natalie C Ward, Gerald F Watts
Clinical and Experimental Pharmacology & Physiology|August 23, 2006
Hypertension and oxidative stressNatalie C Ward, Kevin D Croft
The Lancet. Diabetes & Endocrinology|April 2, 2021
A compass for navigating the perils of hypertriglyceridaemiaGerald F Watts, Natalie C Ward
Heart, Lung & Circulation|January 20, 2021
Extrinsic and Intrinsic Responses in the Development and Progression of AtherosclerosisMariya Kuk, Natalie C Ward, Girish Dwivedi
Current Opinion in Endocrinology, Diabetes, and Obesity|November 24, 2020
Lipoprotein (a) and diabetes mellitus: causes and consequencesNatalie C Ward, Shayimeera Vickneswaran, Gerald F Watts
Current Opinion in Cardiology|December 22, 2018
The gut microbiome and heart failureAdilah F Ahmad, Natalie C Ward, Girish Dwivedi
Current Opinion in Lipidology|October 3, 2019
Lipid management in people with peripheral artery diseaseJonathan Golledge, Natalie C Ward, Gerald F Watts
Diabetes, Obesity & Metabolism|April 20, 2019
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodiesNatalie C Ward, Michael M Page, Gerald F Watts
Frontiers in Cardiovascular Medicine|December 12, 2022
Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intoleranceNatalie C Ward, Christopher M Reid, Gerald F Watts
Pageof 12